Delpor, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative long-acting therapies for chronic conditions, particularly in the central nervous system (CNS). Their flagship product, the DLP-114 risperidone implant, is designed to provide schizophrenia treatment for up to one year following a single administration. This investigational therapy utilizes a sub-dermal implant device that ensures a steady release of medication, thereby improving patient adherence and reducing the risk of relapses associated with non-compliance. The technology aims to address a significant unmet need in mental health treatment by offering a reversible option that can be easily removed if necessary, unlike traditional long-acting injectables.

In addition to the risperidone implant, Delpor is also developing a similar 6-12 month formulation of naltrexone for opioid use disorder and alcohol dependence. Their proprietary delivery systems are designed to maintain a smooth pharmacokinetic profile, minimizing peaks and troughs in drug levels that can lead to adverse effects or sub-therapeutic efficacy. This sustained-release technology not only enhances safety and efficacy but also allows for immediate treatment initiation without complex dosing schedules. Delpor's approach aims to improve overall treatment success while also addressing the cost efficiency of healthcare by reducing the need for frequent physician involvement and hospital visits.

United States

Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.

Delpor, Inc.

Company Details